-
Something wrong with this record ?
Challenges encountered in the transfer of atorvastatin tablet manufacturing - commercial batch-based production as a basis for small-scale continuous tablet manufacturing tests
J. Lyytikäinen, S. Kyllönen, T. Ervasti, E. Komulainen, T. Pekarek, J. Slunečková, J. Leskinen, J. Ketolainen, T. Kubelka, P. Stasiak, O. Korhonen
Language English Country Netherlands
Document type Journal Article
- MeSH
- Atorvastatin MeSH
- Technology, Pharmaceutical * methods MeSH
- Powders chemistry MeSH
- Drug Compounding methods MeSH
- Tablets chemistry MeSH
- Pressure MeSH
- Particle Size MeSH
- Publication type
- Journal Article MeSH
As is the case with batch-based tableting processes, continuous tablet manufacturing can be conducted by direct compression or with a granulation step such as dry or wet granulation included in the production procedure. In this work, continuous manufacturing tests were performed with a commercial tablet formulation, while maintaining its original material composition. Challenges were encountered with the feeding performance of the API during initial tests which required designing different powder pre-blend compositions. After the pre-blend optimization phase, granules were prepared with a roller compactor. Tableting was conducted with the granules and an additional brief continuous direct compression run was completed with some ungranulated mixture. The tablets were assessed with off-line tests, applying the quality requirements demanded for the batch-manufactured product. Chemical maps were obtained by Raman mapping and elemental maps by scanning electron microscopy with energy-dispersive X-ray spectroscopy. Large variations in both tablet weights and breaking forces were observed in all tested samples, resulting in significant quality complications. It was suspected that the API tended to adhere to the process equipment, accounting for the low API content in the powder mixture and tablets. These results suggest that this API or the tablet composition was unsuitable for manufacturing in a continuous line; further testing could be continued with different materials and changes in the process.
Department of Technical Physics University of Eastern Finland Kuopio Finland
School of Pharmacy PromisLab University of Eastern Finland Kuopio Finland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000614
- 003
- CZ-PrNML
- 005
- 20240213093303.0
- 007
- ta
- 008
- 240109e20231011ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijpharm.2023.123509 $2 doi
- 035 __
- $a (PubMed)37832703
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Lyytikäinen, Jenna $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: jenna.lyytikainen@uef.fi
- 245 10
- $a Challenges encountered in the transfer of atorvastatin tablet manufacturing - commercial batch-based production as a basis for small-scale continuous tablet manufacturing tests / $c J. Lyytikäinen, S. Kyllönen, T. Ervasti, E. Komulainen, T. Pekarek, J. Slunečková, J. Leskinen, J. Ketolainen, T. Kubelka, P. Stasiak, O. Korhonen
- 520 9_
- $a As is the case with batch-based tableting processes, continuous tablet manufacturing can be conducted by direct compression or with a granulation step such as dry or wet granulation included in the production procedure. In this work, continuous manufacturing tests were performed with a commercial tablet formulation, while maintaining its original material composition. Challenges were encountered with the feeding performance of the API during initial tests which required designing different powder pre-blend compositions. After the pre-blend optimization phase, granules were prepared with a roller compactor. Tableting was conducted with the granules and an additional brief continuous direct compression run was completed with some ungranulated mixture. The tablets were assessed with off-line tests, applying the quality requirements demanded for the batch-manufactured product. Chemical maps were obtained by Raman mapping and elemental maps by scanning electron microscopy with energy-dispersive X-ray spectroscopy. Large variations in both tablet weights and breaking forces were observed in all tested samples, resulting in significant quality complications. It was suspected that the API tended to adhere to the process equipment, accounting for the low API content in the powder mixture and tablets. These results suggest that this API or the tablet composition was unsuitable for manufacturing in a continuous line; further testing could be continued with different materials and changes in the process.
- 650 _2
- $a atorvastatin $7 D000069059
- 650 _2
- $a prášky, zásypy, pudry $x chemie $7 D011208
- 650 _2
- $a tablety $x chemie $7 D013607
- 650 _2
- $a tlak $7 D011312
- 650 _2
- $a příprava léků $x metody $7 D004339
- 650 12
- $a farmaceutická technologie $x metody $7 D013678
- 650 _2
- $a velikost částic $7 D010316
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kyllönen, Saini $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: sainik@student.uef.fi
- 700 1_
- $a Ervasti, Tuomas $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: tuomas.ervasti@uef.fi
- 700 1_
- $a Komulainen, Eelis $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: eelis.komulainen@uef.fi
- 700 1_
- $a Pekarek, Tomáš $u Zentiva k.s., Prague, Czech Republic. Electronic address: Tomas.Pekarek@zentiva.com
- 700 1_
- $a Slunečková, Jitka $u Zentiva k.s., Prague, Czech Republic. Electronic address: jitka.sluneckova@zentiva.com
- 700 1_
- $a Leskinen, Jari $u Department of Technical Physics, University of Eastern Finland, Kuopio, Finland. Electronic address: jari.leskinen@uef.fi
- 700 1_
- $a Ketolainen, Jarkko $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: jarkko.ketolainen@uef.fi
- 700 1_
- $a Kubelka, Tomáš $u Zentiva k.s., Prague, Czech Republic. Electronic address: Tomas.Kubelka@zentiva.com
- 700 1_
- $a Stasiak, Pawel $u Zentiva k.s., Prague, Czech Republic. Electronic address: pawel.stasiak@zentiva.com
- 700 1_
- $a Korhonen, Ossi $u School of Pharmacy, PromisLab, University of Eastern Finland, Kuopio, Finland. Electronic address: ossi.korhonen@uef.fi
- 773 0_
- $w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 647 (20231011), s. 123509
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37832703 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093300 $b ABA008
- 999 __
- $a ok $b bmc $g 2049332 $s 1210308
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 647 $c - $d 123509 $e 20231011 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
- LZP __
- $a Pubmed-20240109